Drainage device implantation riskier than trabeculectomy

Article

The risk of adverse events following implantation of a glaucoma drainage device (GDD) is higher than the risk following either primary trabeculectomy (PT) or trabeculectomy with scarring (TS), according to results of a study published in the July 2008 issue of Ophthalmology.

The risk of adverse events following implantation of a glaucoma drainage device (GDD) is higher than the risk following either primary trabeculectomy (PT) or trabeculectomy with scarring (TS), according to results of a study published in the July 2008 issue of Ophthalmology.

Frank A. Sloan, PhD of the Center for Health Policy, Duke University, North Carolina, US and colleagues conducted a retrospective, longitudinal cohort analysis of subjects (aged ≥68 years) undergoing PT, TS or GDD implantation between 1994–2003, with follow-up to 2005, to determine rates of postoperative adverse outcomes.

Retinal detachment, endophthalmitis and suprachoroidal haemorrhage were classified as severe complications; choroidal detachment, corneal oedema and hypotony were classified as less serious outcomes.

At the one year follow-up point, severe adverse events in the GDD implantation, TS and PT subject groups were 2.0%, 1.3% and 0.6%, respectively; rates of subjects developing less serious adverse events and low vision/blindness were higher in the GDD group than in the TS and PT groups. After controlling for demographic factors, differences were reduced but not to a statistically significant degree.

Regardless of controlling for demographic factors, the rates of adverse events across the spectrum of severity were slightly higher for patients undergoing GDD implantation than TS or PT surgery.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.